321 ARSENAL STREET, SUITE 101, WATERTOWN, MA
Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
Financial Results, Press Release
Material disclosure
Election of Class III Directors at 2026 Annual Meeting of Stockholders
Reports First Quarter 2026 Financial Results and Provides Business Update
Annual Report to Security Holders
Restructuring Plan Approved; 20% Workforce Reduction at Disc Medicine
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities